446 results about "Microglial cell" patented technology

The invention discloses a scorpion anti-inflammatory polypeptide as well as a screening method and application thereof, and belongs to the technical field of traditional Chinese medicinal material polypeptides. The scorpion anti-inflammatory polypeptide is one of G4, G5 and G17. The method comprises the following steps: detecting a scorpion buthus martensii polypeptide extract through nanoElute 2 nanoliter liquid phase separation, timsTOFPro2 mass spectrometry and BPS Novor search analysis, screening a scorpion buthus martensii polypeptide, and further synthesizing the screened candidate polypeptide by adopting a solid-phase synthesis method; the effect of the synthesized candidate polypeptide on inhibiting microglial cell inflammation is evaluated through a qPCR method, and then the scorpion buthus martensii anti-inflammatory polypeptide is screened out. The Buthus martensii Karsch anti-inflammatory polypeptides G4, G5 and G17 screened by the method, especially G5, can significantly inhibit microglial cell inflammation and present concentration dependence, a theoretical basis is provided for medicinal development of Buthus martensii Karsch polypeptides, and a potential anti-neuroinflammation mechanism of the Buthus martensii Karsch polypeptides is disclosed.

The invention belongs to the field of nutrient substance research, and particularly relates to application of a nutrient composition to regulation of brain immunity. The invention provides application of a nutritional composition in preparation of food for regulating brain immunity. Wherein the nutritional composition comprises the following necessary components: lactoferrin and fucosyllactose, and in the nutritional composition, the mass ratio of the lactoferrin to the fucosyllactose is 1: (0.1-30). Research finds that after lactoferrin and fucosyllactose are combined according to a certain proportion, the lactoferrin and fucosyllactose have a synergistic effect of regulating brain immunity. Experimental data show that after the combination of lactoferrin and fucosyllactose is used for treating the BV2 cells, the trend that the BV2 cells are differentiated into M2 phenotype microglial cells is higher than the trend that the BV2 cells are differentiated into M1 phenotype microglial cells, and the amount of secreted inflammatory factors is obviously reduced.

The invention relates to an exosome composition for improving sleep quality. The exosome composition comprises a lavender exosome, a chamomile exosome and a saffron crocus exosome. The exosome composition disclosed by the invention can be used for improving the expression level of GABA (gamma-aminobutyric acid) related proteins of neuronal cells, promoting the expression of brain-derived neurotrophic factors (BDNF) of the neuronal cells, promoting the synaptic growth of the neuronal cells, improving the CL <-> level of the neuronal cells and inhibiting the inflammatory factor level of microglial cells. The exosome composition disclosed by the invention can be used for improving sleep quality reduction caused by various body discomfort, and has a more obvious using effect than that of the same Chinese herbal medicine extract.

The invention belongs to the technical field of food, and relates to application of breast milk oligosaccharide in regulating brain immunity. Specifically, the invention relates to the non-therapeutic purpose of adjusting brain immunity by adjusting polarization of microglial cells M1 / M2, and the breast milk oligosaccharide is any one of 3-fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose, 3 '-sialic acid lactose and 6'-sialic acid lactose. Research results show that a specific variety of breast milk oligosaccharides (especially 3-FL) can obviously inhibit the generation of neurotoxic factors NO, inflammatory factors TNF-alpha and IL-1beta in microglial cells, and promote the generation of anti-inflammatory cytokines IL-10 in the microglial cells, so that the state of the microglial cells is improved, damage repair is promoted, and the microglial cells are prevented from being damaged. Therefore, the effect of regulating brain immunity is achieved.

The invention discloses application of a cell surface adhesion molecule CD22 as a target spot in preparation of drugs for treating spinal cord injury related diseases. The change of gene expression in the glial scar formation process is represented by space transcriptome sequencing, and the specific expression of CD22 in the glial scar region is up-regulated. According to single cell sequencing, in-situ hybridization and immunohistochemistry, specific high expression CD22 of part of microglial cells in a glial scar area is found. CD22 is knocked out through a genetic means, and it is found that formation of glial scars after spinal cord injury is remarkably reduced through inhibition of CD22. Behavioral detection finds that the error rate of irregular horizontal ladders is remarkably reduced by inhibiting CD22, and fine movement recovery of hind limbs of mice after spinal cord injury is promoted. The siRNA specifically targeting CD22 is injected into the sheath, so that the expression of microglial cells CD22 is inhibited, the error rate of irregular horizontal ladders of hind limbs can be reduced, and the recovery of the fine movement function of the hind limbs of the mouse after spinal cord injury is promoted. The invention provides a new possibility for development of drugs for spinal cord injury and treatment of spinal cord injury.

Conjugation of dendrimer molecules with one or more carbohydrate moieties significantly enhances targeting of tumor-associated macrophages (TAMs) and microglia by increasing brain penetration and cellular internalization, as compared with dendrimers without modification with carbohydrate molecules. Compositions of dendrimers conjugated with carbohydrate moieties, particularly glucose and / or glucosamine, and one or more active agents to prevent, treat, or diagnose a disease or disorder in a subject in need thereof, and methods of use thereof, have been developed. The compositions are particularly suited for treating and / or ameliorating brain and / or CNS tumors. Methods of treating a human subject having or at risk of brain and / or CNS tumors are provided.

The invention relates to the technical field of biological medicine, in particular to a functionalized targeted liposome and application thereof, and the functionalized targeted liposome comprises lipid and a targeted ligand, wherein the targeting ligand can be specifically combined with a TREM2 receptor. According to the lipidosome, the targeting ligand can be specifically combined with the TREM2 receptor, accurate targeting of cells with the surface containing the TREM2 receptor is achieved, it is ensured that the cells directly act on target cells, the accuracy of a delivered substance is further improved, and the lipidosome has the advantages of being targeting, high in stability, small in side effect and high in bioavailability. The functionalized targeted liposome can be applied to the development of drug carriers, pharmaceutical compositions and the like, and has wide application prospects, for example, the liposome is dynamically connected with hydrogel molecules through a borate bond to prepare a hydrogel pharmaceutical composition containing the functionalized targeted liposome, and the application prospect is wide. The liposome disclosed by the invention can respond to an inflammatory environment according to pH and ROS changes of a surrounding environment to release the liposome disclosed by the invention, targets cells with TREM2 receptors on the surfaces, namely microglial cells (with the TREM2 receptors on the surfaces) by virtue of the target ligands exposed on the surfaces, regulates the polarization state of the cells, inhibits the polarization of the cells to a pro-inflammatory M1 type and promotes the polarization of the cells to an anti-inflammatory M2 type, so that the anti-inflammatory effect of the liposome is improved. Therefore, the local microenvironment of the spinal cord injury part is improved, and nerve regeneration is promoted.

The present invention relates to a method for producing microglia-rich brain organoids, comprising the steps of incubating primitive-like macrophages with brain organoids between about 15 and about 30 days old in a low-adhesion cell culture vessel in a brain organoid medium containing CSF-1 to produce microglia. The present invention also relates to microglia-rich brain organoids obtained by the method as described herein.

The invention discloses application of amantadine in inhibition of ITGAV in preparation of medicines for treating dry age-related macular degeneration, and belongs to the technical field of biological medicines. At present, no report for researching the ITGAV gene in the dry AMD exists, the specific action mechanism is not clear, and amantadine adaptation diseases do not include the dry AMD; according to the application disclosed by the invention, the gene target ITGAV is screened from mutual hair generation of microglial cells and RPE cells in a retina microenvironment, and amantadine is used for inhibiting ITGAV protein to relieve the progress of AMD, so that a new thought is provided for treating dry AMD. Experiments show that amantadine can inhibit ITGAV and delay EMT transformation of RPE cells. In a dry AMD mouse model induced by sodium iodate, RPE cell damage can be remarkably relieved by intraocular injection of amantadine, and the structure and function of a retina layer are improved. These results indicate that it may function in early intervention of dry AMD.

The invention belongs to the technical field of biological medicines, and particularly relates to schisandra chinensis exosome-like vesicles and application thereof in preparation of anti-depression products. The schisandra chinensis exosome-like nano-vesicles are prepared by a method of combining differential centrifugation with ultra-high-speed centrifugation. The prepared exosome-like nano vesicles derived from schisandra chinensis can be taken in by nerve microglial cells, and the inflammatory response induced by LPS is inhibited; meanwhile, the LPS-induced mouse depression-like behavior can be improved, and the pathological injury of the hippocampus can be relieved. The invention establishes the preparation method of the schisandra chinensis exosome-like nano-vesicle, and verifies that the schisandra chinensis exosome-like nano-vesicle has an anti-depression effect, so that the schisandra chinensis exosome-like nano-vesicle has a relatively good development and utilization prospect.

The invention relates to an exosome-coated phosphorus-containing dendrimer nano-composite as well as a preparation method and application thereof. The nano-composite is prepared from exosome derived from mesenchymal stem cells, a hydroxyl-terminal phosphorus-containing dendrimer and quercetin. The exosome derived from the mesenchymal stem cells is used as a carrier, so that not only are good biocompatibility and anti-inflammatory activity achieved, but also the bioavailability of the phosphorus-containing dendrimer and quercetin can be improved. The phosphorus-containing dendrimer and quercetin exert anti-inflammatory and anti-oxidation effects by promoting microglial cells to be polarized to M2 type and removing active oxygen, so that neuronal cells are protected from apoptosis. The preparation method has the advantages of being simple, easy to operate, good in biocompatibility and the like, and the provided strategy has good development prospects and application values in treatment of Parkinson's disease or other neurodegenerative diseases.

The invention relates to a phenylpropanoid compound as well as a preparation method and application thereof, in particular to a phenylpropanoid compound extracted from pleione bulbus pseudobulb as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a method for preparing 10 new compounds from pleione bulbocodioides pseudobulb as a raw material for the first time, systematically evaluates the anti-neuroinflammation activity of pleione bulbocodioides pseudobulb, and clarifies the application of pleione bulbocodioides pseudobulb in development and treatment of central nervous system diseases. According to the invention, abnormally activated BV-2 microglial cells induced by LPS (Lipopolysaccharide) are adopted, and the NO release amount is taken as an index, so that the effect of the compound 1-10 on inhibiting excessive activation of the microglial cells is preliminarily evaluated. The result shows that the novel compounds 1-10 can inhibit the release of LPS-induced BV-2 microglial cell NO. Therefore, the compound prepared in the invention can be applied to development of drugs for treating central nervous system diseases.

The present invention relates to a model mouse with a microglia-specific vitamin D binding protein (VDBP) gene knocked out and a construction method therefor. The construction method comprises the following steps: constructing a VDBPloxp / loxp gene mouse; hybridizing the VDBPloxp / loxp gene mouse with a Cre / ERT2 gene mouse to obtain a Cre+ / --VDBP+ / + gene mouse, wherein the microglia of the Cre / ERT2 gene mouse carry Cre gene; and inducing the expression of the Cre gene in the Cre+ / --VDBP+ / + gene mouse to obtain the model mouse with a microglia-specific VDBP gene knocked out. According to the construction method, a VDBP in the microglia of the model mouse can be specifically knocked out on the basis of Cre-loxP recombination, specific knockdown of the expression of the gene of the VDBP in the microglia is achieved, and the knockdown efficiency reaches 80% or more, facilitating more detailed study of the function of the molecule in the brain.

The invention discloses application of LW6 in preparation of drugs for preventing and treating neuroinflammation and protecting microglial cells. Cell experiments prove that the LW6 can inhibit the expression of HIF-1alpha protein in LPS-induced microglial cells BV2, can inhibit the mRNA expression level of inflammatory factors IL-1beta and IL-6 in the microglial cells BV2, and can inhibit the mRNA expression level of microglial cell inflammatory enzyme iNOS, which indicates that the LW6 can protect the microglial cells and prevent and treat neuroinflammation, and has a significant effect on degenerative diseases such as Alzheimer's disease. The compound has certain significance in treating Parkinson's disease, and can be used for preparing medicines for preventing and treating neuroinflammation and medicines for protecting microglial cells.

The invention discloses a preparation and purification method and application of a quinoline derivative with biological activity, and belongs to the technical field of medicine synthesis. According to the key points of the technical scheme, the quinoline derivative molecule has a structure # imgabs0 #, wherein X is NH or empty (benzene rings are directly connected); r is an aromatic ring derivative or alkyl or other groups. The invention designs and synthesizes a quinoline derivative with a novel structure, and the compound has a relieving effect on LPS-induced microglial cell inflammation and has a certain inhibition effect on cervical cancer cells.

The invention relates to the technical field of biological medicine, and particularly discloses application of Si-Ikzf1 in preparation of products for inflammation treatment and neuroprotection, the Si-Ikzf1 provided in the scheme of the invention reduces formation of cell eschar by promoting microglial cell MResident subtype to be generated into MPtn subtype instead of MIkzf1, and improves post-ICH neurological functions by regulating Ikzf1-SIRT1 and downstream signal pathways thereof. The scheme of the invention reveals high expression of inflammatory bodies and scorch symptom related proteins in MIkzf1 subtype microglial cells, and Si-Ikzf1 can promote the conversion of MResident in ICH rats to MPtn instead of MIkzf1, and the MPtn represents an anti-inflammatory effect of promoting nerve remodeling, and the Si-Ikzf1 is capable of promoting the conversion of MResident in ICH rats to MPtn in ICH rats to MPtn in ICH rats to MPtn in ICH rats to MPtn in ICH rats. It is revealed that Si-Ikzf1 hinders MIkzf1 inflammation, scorch symptom and cell apoptosis, so that cognitive behavior and demyelination injury are improved; moreover, the scheme of the invention proves that the Si-Ikzf1 can reverse the reduction of SIRT1 expression in BV-2 cells and ICH rat brains after inflammation stimulation, and promote the up-regulation of Ptn in MPtn.

The invention discloses a boron difluoride curcumin skeleton compound as shown in a formula (I), and belongs to the field of medical imaging molecular probes. The boron difluoride curcumin skeleton compound disclosed by the invention has the characteristics of near-infrared emission and large Stokes shift, can be used as a fluorescent probe for marking key pathological proteins such as beta-amyloid protein (Abeta) aggregate of Alzheimer's disease (AD) and the like, and has the characteristics of high sensitivity, high signal-to-noise ratio and high imaging; in addition, in-vivo level A beta imaging can be realized through a blood brain barrier. The boron difluoride curcumin skeleton compound disclosed by the invention also has a treatment effect and can be used for remarkably inhibiting A beta monomers from forming aggregates and depolymerizing A beta aggregates, and meanwhile, the compound shown as the formula (I) is used for remarkably inhibiting A beta-induced microglial cell inflammatory response. The invention also provides a preparation method of the boron difluoride curcumin skeleton compound, an intermediate compound and application of the boron difluoride curcumin skeleton compound. # imgabs0 #

The invention relates to the technical field of biological medicine, in particular to application of halofuginone in medicine for treating spinal cord injury. The invention provides application of halofuginone in preparation of a medicine for treating spinal cord injury, application of halofuginone in preparation of a medicine for promoting spinal cord injury repair and application of halofuginone in preparation of a medicine for promoting exercise ability recovery after spinal cord injury. The therapeutic drug can promote functional recovery after spinal cord injury, inhibit activation of microglial cells after spinal cord injury and reduce inflammatory response. In addition, the treatment medicine can prevent neuronal reduction after spinal cord injury.

The invention discloses pediococcus acidilactici for improving offspring social behaviors of a parent and application thereof, and belongs to the technical field of microorganisms. According to the pediococcus acidilactici CCFM1344 provided by the invention, by intervening neurodysplasia caused by high-fat diet of a parent body, the improvement of hyperactivity and social behaviors of the offspring is specifically shown as follows: (1) hyperactivity disorder, induced by high-fat diet of the parent body, of the offspring in juvenile and adult periods is recovered; (2) restoring parent high-fat diet induced social contact disorders of offspring juveniles and adult periods; (3) reducing the gene expression of the small glial cell M1 type differentiation marker CD86 in the offspring hippocampus; and (4) reducing the gene expression of the macrophage activation marker F4 / 80 in the offspring hippocampus. Through the probiotic preparation containing the pediococcus acidilactici CCFM1344, a new thought and method can be provided for early intervention of the autism spectrum disorder.

The present invention relates to a branched fatty acid composition and its use in assisting the maintenance of nervous system health, and belongs to the field of nutrient research. The branched fatty acid composition provided by the present invention comprises C14:0, C15:0, C16:0 and C17:0. After LPS-induced microglia are treated with the branched fatty acid composition, the trend that the microglia can be promoted to differentiate into M2 phenotype microglia is higher than the trend that the microglia are promoted to differentiate into M1 phenotype microglia, while promoting the secretion of anti-inflammatory factors such as IL-4 and IL-10, and inhibiting the secretion of pro-inflammatory factors such as NO, TNF-a, and IL-1β. C14:0, C15:0, C16:0 and C17:0 in the branched fatty acid composition have a good synergistic effect, which plays a role in regulating brain immunity and maintaining the health of the central nervous system.

The invention belongs to the technical field of biological medicine, and particularly relates to an extracellular vesicle drug delivery system, a preparation method thereof and application of the extracellular vesicle drug delivery system in treatment of Alzheimer's disease. According to the invention, one or more of stilbene glucoside, emodin, kaempferol, resveratrol and quercetin are used for regulating and controlling the expression of miRNA (micro Ribonucleic Acid) related to the disease progress in the extracellular vesicles, and the result shows that one or more of miR-let-7c-5p, miR-486-5p, miR-132-3p, miR-160b and miR-129-5p is remarkably up-regulated, and one or more of miR-342-3p, miR-16-5p and miR-125b-5p is remarkably down-regulated. The regulated extracellular vesicles can be used for treating Alzheimer's disease, relieving Tau protein abnormal phosphorylation, reducing amyloid protein beta deposition, inhibiting microglial cell activation, protecting neuronal cells and relieving memory deficits.

The invention belongs to the technical field of biological medicines, and relates to application of achyranthes bidentata polypeptide combined with human umbilical cord mesenchymal stem cell exosome in preparation of a medicine for preventing and / or treating Parkinson's disease, the achyranthes bidentata polypeptide combined with the human umbilical cord mesenchymal stem cell exosome is used for treating mice, and 1-methyl-4-phenyl-1, 2, 3, 4-tetramethyl-1, 3, 4-tetramethyl-1, 3, 4-tetramethyl-1, 3, 4-tetramethyl-1, 3, 4-tetramethyl-1, 3, 4-tetramethyl-1, 3, 4 The method comprises the following steps: carrying out Parkinson model (PD) modeling on a mouse by using 2, 3, 4, 6-tetrahydropyridine (MPTP); it is found that the treatment can significantly relieve PD related symptoms, for example, the number of dopaminergic neurons in a nigra part is recovered, expression of tyrosine hydroxylase in a middle brain part is improved, movement and olfactory dysfunction of a PD model mouse is relieved, activation of olfactory bulbs and microglia and astrocytes in the middle brain part is reduced, and activity of neurons in the olfactory bulbs is improved.

Devices, systems, and methods for a treating dementia or Alzheimer's disease in a subject in need thereof. In one example, combined auditory and visual stimuli having a frequency of about 20 Hz to about 60 Hz, and more specifically about 40 Hz, are non-invasively delivered to the subject to induce synchronized gamma oscillations in at least one brain region of the subject. In particular, pursuant to various treatment and exposure protocols, combined auditory and visual stimulation (as opposed to auditory or visual stimulation alone) promotes a microglia response in the medial prefrontal cortex (mPFC). More generally, combined auditory and visual stimulation induces an extended microglia clustering response in the auditory cortex, the visual cortex, and the mPFC.

The invention discloses a method for efficiently and rapidly differentiating microglial cells. According to the invention, the iPSC is creatively differentiated into the neural stem cells, and then the neural stem cells are induced and differentiated to obtain the microglial cells. The microglial cells obtained by applying the scheme show excellent homogeneity and relatively high yield; the differentiation scheme is simple and convenient, and microglial cells with relatively high purity can be obtained without suspension culture or a low-oxygen environment; meanwhile, the method disclosed by the invention is short in time consumption, the microglial cells with relatively high purity can be obtained only in 14 days, and the differentiation time is greatly shortened.

The invention provides multifunctional bionic hydrogel as well as preparation and application thereof in traumatic brain injury treatment, and belongs to the field of biomedical materials. The preparation method comprises the following steps: combining polydopamine modified hemoglobin nanoparticles with curcumin-based carbon quantum dots with anti-inflammatory activity, and embedding into bionic hyaluronic acid-collagen double-network hydrogel, so as to prepare the multifunctional bionic hydrogel. The hydrogel can effectively relieve neuron hypoxia, reduce apoptosis, promote the polarity of microglial cells to be converted into anti-inflammatory phenotype, and significantly down-regulate the expression of S100A8, thereby inhibiting pathological neural immune crosstalk. In a traumatic brain injury model, hydrogel implantation improves the pathological microenvironment, enhances endogenous nerve regeneration, and ultimately results in significant neurological function and cognitive recovery. The multifunctional bionic hydrogel prepared by the invention has a good application prospect in preparation of materials for preventing and / or treating traumatic brain injury.

The invention discloses a nasal delivery multistage targeting bionic nano drug delivery system as well as a preparation method and application of the nasal delivery multistage targeting bionic nano drug delivery system. According to the drug delivery system, a black phosphorus nanosheet with an active oxygen scavenging effect is used as an inner core carrier, a neuroprotective agent fingolimod hydrochloride FTY720 and polydimethyldiguanide PolyMet are loaded, and a microcolloid cell membrane and a mitochondrial membrane are modified on the surface of the preparation; the nano drug delivery system is applied to treatment of cerebral arterial thrombosis reperfusion injury, can overcome the blood brain barrier, can quickly enter the brain through nasal administration, realizes efficient delivery of drugs, remarkably reduces the cerebral infarction area, reduces the brain inflammation level, protects nerve cells, greatly relieves cerebral arterial thrombosis reperfusion injury, and has application prospects.

The invention discloses a DNA tetrahedral framework, a nano-composite and application of the nano-composite in treatment of spinal cord injury, and relates to the field of biological medicine, the DNA tetrahedral framework capable of loading ginger-derived exosome-like nanoparticles GELN is researched and developed, the DNA tetrahedral framework comprises four DNA single chains, nucleotide sequences of the four DNA single chains have at least 80% identity with sequences shown in SEQ ID NO: 1-4 respectively, and the DNA single chains are used for loading ginger-derived exosome-like nanoparticles GELN. The novel nano-composite obtained by compounding the DNA tetrahedral framework and GELN can target and enduringly act on microglial cells, and a way is provided for development of drugs for spinal cord injury and research of related pathological mechanisms.

The invention discloses a construction method of a human microglial cell model carrying ENTPD1 gene mutation, and the human microglial cell model is prepared by the following steps: extracting PBMC from venous blood of a hereditary spasmodic paraplegia patient, then electrically transforming four factors of Oct4, Sox2, Klf4 and cMyc, and culturing in a Matrigel-coated culture dish for 15-20 days to obtain induced pluripotent stem cells; the induced pluripotent stem cells can form a unique human microglial cell model, and the human microglial cell model and the induced pluripotent stem cells are co-cultured to obtain an organoid, so that the analysis of a pathogenic molecular mechanism behind a disease risk gene is greatly facilitated, the defects of a rodent-derived microglial cell model are complemented, and the development of the rodent-derived microglial cell model is promoted. And the influence of the ENTPD1 on the related functions of the microglial cells is further discussed.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a bionic nano-drug delivery system for targeted regulation of microglial cell immune function, in particular to a bionic nano-drug delivery system for targeted regulation of microglial cell immune function and having the effect of an immune checkpoint inhibitor and application of the bionic nano-drug delivery system in brain glioma immunotherapy. The drug delivery system is a bionic nano drug delivery system prepared from an oleanolic acid nanocrystal core (OA-core), an M0 or M2 type macrophage membrane and an acid-sensitive lipid material connected with immune checkpoint antagonistic polypeptide. The bionic nano-drug delivery system constructed by the invention can realize co-loading of small molecule drugs and polypeptide drugs and precise delivery and graded release of focus parts, regulates and controls the brain glioma immune process in a multi-target manner, synergistically enhances the anti-glioma immune effect, and has a wide application prospect.

The invention provides novel application of gastrodin, and belongs to the technical field of biological medicine. By constructing an MCAO model of cerebral arterial thrombosis and detecting the influence of GAS on MCAO mouse and OGD-induced microglial cell ferroptosis, it is found that GAS alleviates the ferroptosis of cerebral arterial thrombosis, it is found through molecular docking and cell thermal displacement experiments that GAS is specifically bound with Alkbh5, the stability of protein is improved, nuclear translocation of Alkbh5 is promoted, and the GAS can be used for treating cerebral arterial thrombosis. Therefore, the methylation level of N6-methyladenosine (m6A) of a glutamic acid-cysteine ligase modified subunit (Gclm) is reduced, the expression of the Gclm is increased, the synthesis of glutathione is enhanced, and finally ferroptosis of microglial cells is inhibited. Therefore, the gastrodin can be used for preparing the medicine for treating the ferroptosis of the cerebral arterial thrombosis, and a new natural medicine source is provided for preventing and treating the ferroptosis of the cerebral arterial thrombosis.